Objective testing of near vision

Article

Although near vision can never be assessed objectively, standardization between tests would be useful. However, as Dr Oliver Findl demonstrated, there is a lack of standardization between tests so that comparison of results of different near vision tests is difficult, or not possible.

High incidence of presbyopia in patients over the age of 45 years and a growing demand for spectacle independence has lead to an increasing interest in presbyopia treatments, such as multifocal intraocular lenses, so-called accommodating IOLs, different kinds of corneal treatments and lens refilling, as alternatives to wearing reading glasses. This was the message from Austria’s Oliver Findl, speaking on the last day of the ESCRS Congress in Paris.

Results of these treatments are usually evaluated using near or reading vision as main outcome parameters. Although near vision can never be assessed objectively, standardization between tests would be useful. However, there is a lack of standardization between tests so that comparison of results of different near vision tests is difficult, or not possible.

Although reading vision can never be measured objectively, it should be the aim to measure reading vision under standardized conditions. Until today, many different reading charts are in use and reading conditions vary between clinical centres and even between patients.

When presbyopic treatments are evaluated, it should be taken into account that pseudoaccomodation strongly influences the subjective accommodative response measurements, such as the push-up test as well as defocus curve testing. Additionally, macular and cortical function related to visual perception are known to play a role in extracting information from a defocused image, such as deciphering blurred optotypes from a reading chart. These effects can result in good uncorrected distance and near vision in patients, whether presbyopia was treated, or not.

There is a need for a reliable and comparable system for evaluation of reading performance to be able to follow-up patients after treatment and to compare groups receiving different treatments. This would also allow aggregation of data from different centres in multicentre trials.

Read a more detailed report on Dr Findl’s paper in OTEurope October.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.